Barclays lowered the firm’s price target on Regenxbio to $50 from $55 and keeps an Overweight rating on the shares. The company announced 77% and 47% protein levels per western blot for two additional Duchenne muscular dystrophy patients treated with RGX-202, the analyst tells investors in a research note. The firm says Regenxbio’s programs remained on track in Q2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio reports Q2 EPS ($1.05), consensus ($1.29)
- REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
- Biotech Alert: Searches spiking for these stocks today
- Regenxbio’s RGX-202 shows positive Phase 1/2 results in Duchenne
- RegenXBio Inc. (RGNX) Q2 Earnings Cheat Sheet